This study investigates the prognostic value of serum biomarkers PD-L1 and IGFBP-2 in patients with esophageal carcinoma. It finds a significant positive correlation between these biomarkers and established tumor markers CEA and CYFRA21-1. The 3-year survival rate for the patient cohort was 45.10%, with deceased patients showing significantly higher levels of PD-L1 and IGFBP-2. ROC analysis indicates a strong predictive value for these biomarkers, with combined use potentially enhancing diagnostic accuracy. Kaplan-Meier curves reveal lower survival rates for patients with high biomarker expression. The study suggests that PD-L1 and IGFBP-2 could be valuable for clinical management and prognostic evaluation of esophageal carcinoma patients.